Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia

Genome-wide studies have identified a high-risk subgroup of pediatric acute lymphoblastic leukemia (ALL) harboring mutations in the Janus kinases (JAKs). The purpose of this study was to assess the preclinical efficacy of the JAK1/2 inhibitor, AZD1480, both as a single agent and in combination with...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Mol Cancer Ther
Egile Nagusiak: Suryani, Santi, Bracken, Lauryn S., Harvey, Richard C., Sia, Keith C.S., Carol, Hernan, Chen, I-Ming, Evans, Kathryn, Dietrich, Philipp A., Roberts, Kathryn G., Kurmasheva, Raushan T., Billups, Catherine A., Mullighan, Charles G., Willman, Cheryl L., Loh, Mignon L., Hunger, Stephen P., Houghton, Peter, Smith, Malcolm A., Lock, Richard B.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2014
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4326541/
https://ncbi.nlm.nih.gov/pubmed/25504635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0647
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak